Share

December 2015; 2 (6) ArticleOpen Access

Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy

Evelyn Dubois, Christoph Ruschil, Felix Bischof
First published October 29, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000177
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
748

Share

Article Information

vol. 2 no. 6 e177
DOI: 
https://doi.org/10.1212/NXI.0000000000000177
PubMed: 
26568972
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 4, 2015
  • Accepted in final form September 23, 2015
  • First Published October 29, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Evelyn Dubois,
    2. Christoph Ruschil, MD and
    3. Felix Bischof, MD
  1. Evelyn Dubois,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Christoph Ruschil, MD and
    3. Scientific Advisory Boards:

    1. (1) Novartis Pharma GmbH

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Felix Bischof, MD
    4. Scientific Advisory Boards:

    1. FB received compensation for serving on Scientific Advisory Boards for Genzyme, Novartis and Roche. The other authors declare that they have no competing interests.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. FB received speaker honoraria and travel support from Biogen Idec, Genzyme and Novartis.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. FB received research support from Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Center of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Germany.
  1. Correspondence to Dr. Bischof: felix.bischof{at}uni-tuebingen.de

Article usage

Article usage: October 2015 to November 2023

AbstractFullPdfSource
Oct 2015632611Highwire
Nov 201518121217Highwire
Nov 201503122pmc
Dec 20152082025Highwire
Dec 201503019pmc
Jan 201657914Highwire
Jan 20160147pmc
Feb 20163477Highwire
Feb 2016085pmc
Mar 20165029Highwire
Mar 20160186pmc
Apr 201628210Highwire
Apr 20160138pmc
May 20162466Highwire
May 2016095pmc
Jun 201630214Highwire
Jun 2016062pmc
Jul 20162603Highwire
Jul 2016033pmc
Aug 20162621Highwire
Aug 2016072pmc
Sep 2016820Highwire
Sep 20160100pmc
Oct 20161912Highwire
Oct 20160124pmc
Nov 20161012Highwire
Nov 2016063pmc
Dec 20161410Highwire
Dec 2016075pmc
Jan 20171711Highwire
Jan 2017072pmc
Feb 20171401Highwire
Feb 20170103pmc
Mar 20171030Highwire
Mar 2017092pmc
Apr 20171310Highwire
Apr 201711316pmc
May 2017761Highwire
May 201721821pmc
Jun 20171022Highwire
Jun 20170910pmc
Jul 2017340Highwire
Jul 2017089pmc
Aug 2017921Highwire
Aug 2017055pmc
Sep 2017230Highwire
Sep 2017274pmc
Oct 2017711Highwire
Oct 2017088pmc
Nov 2017821Highwire
Nov 201731414pmc
Dec 2017060Highwire
Jan 2018081Highwire
Feb 2018043Highwire
Mar 20180101Highwire
Apr 2018092Highwire
Apr 2018177pmc
May 20180324Highwire
Jun 20180233Highwire
Jun 2018234pmc
Jul 20180252Highwire
Aug 20182413Highwire
Aug 2018044pmc
Sep 20181373Highwire
Oct 20181246Highwire
Nov 20180490Highwire
Dec 201801092Highwire
Jan 20191881Highwire
Feb 20192764Highwire
Mar 20190192Highwire
Apr 2019175Highwire
May 20193106Highwire
Jun 20192316Highwire
Jul 20193476Highwire
Aug 20192127Highwire
Sep 20191106Highwire
Oct 20191141Highwire
Nov 20190154Highwire
Dec 20190132Highwire
Jan 20200131Highwire
Feb 20201113Highwire
Mar 20202106Highwire
Apr 20200101Highwire
May 2020074Highwire
Jun 2020173Highwire
Jul 20200354Highwire
Aug 20201112Highwire
Sep 20205324Highwire
Oct 202002311Highwire
Nov 20201174Highwire
Dec 20201133Highwire
Jan 20211138Highwire
Feb 2021289Highwire
Mar 20211127Highwire
Apr 20213172Highwire
May 20211175Highwire
Jun 20213120Highwire
Jul 202141217Highwire
Aug 20216255Highwire
Sep 20211168Highwire
Oct 20213313Highwire
Nov 202121621Highwire
Dec 20215218Highwire
Jan 2022073Highwire
Feb 202251814Highwire
Mar 20221153Highwire
Apr 20220149Highwire
May 202221617Highwire
Jun 20221266Highwire
Jul 20220200Highwire
Aug 202233119Highwire
Sep 202223616Highwire
Oct 202233515Highwire
Nov 202256120Highwire
Dec 20221285Highwire
Jan 20233376Highwire
Feb 20233389Highwire
Mar 20231296Highwire
Apr 20231245Highwire
May 20233246Highwire
Jun 20232163Highwire
Jul 202322211Highwire
Aug 20231317Highwire
Sep 20232226Highwire
Oct 20232143Highwire
Nov 20230121Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles